Search tips
Search criteria 


Logo of neuroscibullNeuroscience Bulletin
Neurosci Bull. 2009 December; 25(6): 343–352.
Published online 2009 November 26. doi:  10.1007/s12264-009-0513-3
PMCID: PMC5552501

Language: English | Chinese

Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status

咖啡酸、 罗非考昔及两者连用对喹啉酸诱导的大鼠行为变化及谷胱甘肽氧化还原紊乱的改善与修复作用



The neuroprotective roles of cyclooxygenase (COX) and lipooxygenase (LOX) inhibitors have been well documented. Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington’s disease (HD), by stimulating NMDA receptors. However, the exact roles of COX and LOX inhibitors in HD have not yet been explained. The present study aims to elucidate the effects of caffeic acid (a specific inhibitor for LOX), rofecoxib (a specific inhibitor for COX-2), and their combination in ameliorating QAinduced neurotoxicity in rats.


QA was injected into the right striatum of rats to induce neurotoxicity. Caffeic acid and rofecoxib were then orally administered separately. In the combination study, caffeic acid and rofecoxib were administered together. After that, a series of behavioral assessments were conducted to determine the effects of caffeic acid and rofecoxib, respectively, and the co-effect of caffeic acid and rofecoxib, against QA-induced neurotoxicity.


Intrastriatal QA administration (300 nmol) not only induced a significant reduction in body weight and motor incoordination, but also altered the redox status (decreased glutathione and increased oxidized glutathione level) in striatum, as compared to the sham group. Moreover, chronic treatment with caffeic acid (5 mg/kg and 10 mg/kg, respectively, p.o.) or rofecoxib (10 mg/kg, p.o.) could significantly attenuate QA-induced behavioral alterations and restore the redox status in striatum. However, at the dose of 2.5 mg/kg, caffeic acid did not show any significant effects on these parameters in QA-treated rats. Furthermore, the combination of rofecoxib (10 mg/kg) and caffeic acid (5 mg/kg) could significantly protect against QA neurotoxicity.


The in vivo study indicates that excitotoxic injury to the brain might affect oxidant/antioxidant equilibrium by eliciting changes in glutathione. Moreover, the LOX and the COX pathways may be both involved in quinolinic-induced neurotoxicity, which provides a promising target for HD treatment.

Keywords: caffeic acid, cyclooxygenase, glutathione, quinolinic acid, rofecoxib



环氧和酶(COX)抑制剂和脂肪氧化酶(LOX)抑制剂已被证实具有神经保护作用, 但对其具体机制目前研究甚少。 喹啉酸具有兴奋毒性作用, 通过激活NMDA 受体, 引起类似于亨廷顿舞蹈症 (Huntington’s Disease, HD) 的症状, 包括行为、 形态以及生化水平上的各种异常。 本研究旨在探讨咖啡酸(LOX特异性抑制剂)和罗非考昔(COX特异性抑制剂)各自以及两者连用对喹啉酸引起的大鼠神经毒性的改善和修复作用。


在大鼠右侧纹状体内注射喹啉酸, 诱导神经毒性。 随后每天给大鼠口服咖啡酸或罗非考昔, 或两者同时服用。 用一系列行为学及生化检测方法检测咖啡酸和罗非考昔, 以及两者连用对喹啉酸诱导的大鼠行为变化及谷胱甘肽氧化还原紊乱的改善和修复作用。


在纹状体注射喹啉酸不仅能降低大鼠体重, 引起运动失调, 而且能破坏纹状体内氧化还原间的平衡, 表现为谷胱甘肽水平降低, 以及氧化谷胱甘肽水平升高。 长期服用咖啡酸或罗非考昔, 以及两者连用都能显著减轻喹啉酸引起的行为变化, 修复氧化还原水平的平衡。 而当剂量为2.5 mg/kg 时, 咖啡酸未表现出任何保护作用。


本实验结果表明, 大脑的兴奋性中毒有可能通过改变谷胱甘肽的水平影响氧化与抗氧化间的平衡。 环氧合酶和脂肪氧化酶通路都可能参与了喹啉酸诱导的神经毒性过程。 这些结果为治疗HD提供了研究靶点。

关键词: 咖啡酸, 环氧合酶, 谷胱甘肽, 喹啉酸, 罗非考昔


[1] Beal M.F. Neurochemistry and toxin models in Huntington’s disease. Curr Opin Neurol. 1994;7(6):542–547. doi: 10.1097/00019052-199412000-00012. [PubMed] [Cross Ref]
[2] Sanberg P.R., Calderon S.F., Giordano M., Tew J.M., Norman A.B. The quinolinic acid model of Huntington’s disease: locomotor abnormalities. Exp Neurol. 1989;105:45–53. doi: 10.1016/0014-4886(89)90170-2. [PubMed] [Cross Ref]
[3] Furtado J.C., Mazurek M.F. Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington’s disease. Exp Neurol. 1996;138(1):158–168. doi: 10.1006/exnr.1996.0054. [PubMed] [Cross Ref]
[4] Roberts R.C., Ahn A., Swartz K.J., Beal M.F., DiFiglia M. Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp Neurol. 1993;124(2):274–282. doi: 10.1006/exnr.1993.1197. [PubMed] [Cross Ref]
[5] Norman A.B., Giordano M., Sandberg P.R. Fetal striatal tissue graft into excitotoxin-lesioned striatum: pharmacological and behavioral aspects. Pharmacol Biochem Behav. 1989;34:139–147. doi: 10.1016/0091-3057(89)90365-1. [PubMed] [Cross Ref]
[6] Reynolds N.C., Lin W., Cameron C.M., Roerig D.L. Differential response of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat. Brain Res. 1997;778:140–149. doi: 10.1016/S0006-8993(97)01048-2. [PubMed] [Cross Ref]
[7] Choi D.W. Excitotoxic cell death. J Neurobiol. 1992;23(9):1261–1276. doi: 10.1002/neu.480230915. [PubMed] [Cross Ref]
[8] Hurley S.D., Olschowka J.A., O’Banion M.K. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma. 2002;19(1):1–15. doi: 10.1089/089771502753460196. [PubMed] [Cross Ref]
[9] Kukreja R.C., Kontos H.A., Hess M.L., Ellis E.F. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res. 1986;59(6):612–619. [PubMed]
[10] Benzi G., Moretti A. Age- and peroxidative stress-related modifi cations of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic Biol Med. 1995;19(1):77–101. doi: 10.1016/0891-5849(94)00244-E. [PubMed] [Cross Ref]
[11] Cooper J.L., Meister A. Glutathione in the brain: disorders of glutathione metabolism. In: Rosenberg A., editor. The Molecular and Genetic Basis of Neurological Disorders. New York: Ruttle Graphics; 1992. pp. 209–238.
[12] Gerlach M., Riederer P., Youdim M.B.H. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. In: Battistin L., Scarlato G., Caraceni T., Ruggieri S., editors. Parkinsons Disease, vol. 69. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 177–194. [PubMed]
[13] Krieglstein J. Excitotoxicity and neuroprotection. Eur J Pharm Sci. 1997;5:181–187. doi: 10.1016/S0928-0987(97)00276-5. [Cross Ref]
[14] Froissard P., Monrocq H., Duval D. Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells. Eur J Pharmacol. 1997;326:93–99. doi: 10.1016/S0014-2999(97)00155-6. [PubMed] [Cross Ref]
[15] Kart A, Cigremis Y, Karaman M, Ozen H. Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exp Toxicol Pathol 2009, 4 [Epub ahead of print]. [PubMed]
[16] Sul D., Kim H.S., Lee D., Joo S.S., Hwang K.W., Park S.Y. Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci. 2009;84(9–10):257–262. doi: 10.1016/j.lfs.2008.12.001. [PubMed] [Cross Ref]
[17] Rahamathulla M., Hv G., Rathod N. Solubility and dissolution improvement of Rofecoxib using solid dispersion technique. Pak J Pharm Sci. 2008;21(4):350–355. [PubMed]
[18] Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 6th edition. San Diego: Academic Press; 2007. p. 256.
[19] Kumar P., Padi S.S., Naidu P.S., Kumar A. Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007;21(3):297–306. doi: 10.1111/j.1472-8206.2007.00485.x. [PubMed] [Cross Ref]
[20] Kulkarni SK. Hand book of experimental pharmacology (3rd edition). Delhi, Vallabh Prakashan, 1999.
[21] Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–77. doi: 10.1016/0003-9861(59)90090-6. [PubMed] [Cross Ref]
[22] Zahler W.L., Cleland W.W. A specific and sensitive assay for disulfides. J Biol Chem. 1968;243:716–719. [PubMed]
[23] Gornall A.G., Bardawill C.J., David M.M. Determination of serum proteins by means of the biuret reaction. J Biol Chem. 1949;177(2):751–766. [PubMed]
[24] Moyanova S.G., Kortenska L.V., Mitreva R.G., Pashova V.D., Ngomba R.T., Nicoletti F. Multimodal assessment of neuroprotection applied to the use of MK-801 in the endothelin-1 model of transient focal brain ischemia. Brain Res. 2007;11(1153):58–67. doi: 10.1016/j.brainres.2007.03.070. [PubMed] [Cross Ref]
[25] Estrada Sánchez A.M., Mejía-Toiber J., Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch Med Res. 2008;39(3):265–276. doi: 10.1016/j.arcmed.2007.11.011. [PubMed] [Cross Ref]
[26] Obrenovitch T.P. Quinolinic acid accumulation during neuroinflammation. Does it imply excitotoxicity? Ann N Y Acad Sci. 2001;939:1–10. [PubMed]
[27] Datta K., Biswal S.S., Kehrer J.P. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J. 1999;1(340):371–375. doi: 10.1042/0264-6021:3400371. [PubMed] [Cross Ref]
[28] Klegeris A., McGeer P.L. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging. 2002;23(5):787–794. doi: 10.1016/S0197-4580(02)00021-0. [PubMed] [Cross Ref]
[29] Bishnoi M., Patil C.S., Kumar A., Kulkarni S.K. Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology. 2007;79(1):34–41. doi: 10.1159/000097627. [PubMed] [Cross Ref]
[30] Wise-Faberowski L., Pearlstein R.D., Warner D.S. NMDA-induced apoptosis in mixed neuronal/glial cortical cell cultures: the effects of isoflurane and dizocilpine. J Neurosurg Anesthesiol. 2006;18(4):240–246. doi: 10.1097/00008506-200610000-00004. [PubMed] [Cross Ref]
[31] Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease. J Neurosci. 1991;11(6):1649–1659. [PubMed]
[32] Vazey E.M., Chen K., Hughes S.M., Connor B. Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington’s disease. Exp Neurol. 2006;199(2):384–396. doi: 10.1016/j.expneurol.2006.01.034. [PubMed] [Cross Ref]
[33] Borlongan C.V., Randall T.S., Cahill D.W., Sanberg P.R. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Brain Res. 1995;676:231–234. doi: 10.1016/0006-8993(95)00150-O. [PubMed] [Cross Ref]
[34] Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., et al. Plastic and behavioral abnormalities in experimental Huntington’s disease: a crucial role for cholinergic interneurons. Neurobiol Dis. 2006;22(1):143–152. doi: 10.1016/j.nbd.2005.10.009. [PubMed] [Cross Ref]
[35] Scattoni M.L., Valanzano A., Pezzola A., March Z.D., Fusco F.R., Popoli P., et al. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington’s disease. Behav Brain Res. 2007;176(2):216–221. doi: 10.1016/j.bbr.2006.10.004. [PubMed] [Cross Ref]
[36] Bordelon Y.M., Chesselet M.F., Ereciñska M., Silver I.A. Effects of intrastriatal injection of quinolinic acid on electrical activity and extracellular ion concentrations in rat striatum in vivo. Neuroscience. 1998;83(2):459–469. doi: 10.1016/S0306-4522(97)00421-1. [PubMed] [Cross Ref]
[37] Tang T.S., Slow E., Lupu V., Stavrovskaya I.G., Sugimori M., Llinás R., et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease. Proc Natl Acad Sci U S A. 2005;102(7):2602–2607. doi: 10.1073/pnas.0409402102. [PubMed] [Cross Ref]
[38] Soliman D, Hamming KS, Matemisz LC, Light PE. Reactive oxygen species directly modify sodium-calcium exchanger activity in a splice variant-dependent manner. J Mol Cell Cardiol. 2009, May 27 [Epub ahead of print]. [PubMed]
[39] Nicholls DG. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta 2009, Mar 17 [Epub ahead of print] [PMC free article] [PubMed]
[40] Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, Andrews SB. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci U S A 2009, May 29 [Epub ahead of print] [PubMed]
[41] Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 2001;14(9):1492–1504. doi: 10.1046/j.0953-816x.2001.01767.x. [PubMed] [Cross Ref]
[42] Kelley K.A., Ho L., Winger D., Freire-Moar J., Borelli C.B., Aisen P.S., et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999;155(3):995–1004. [PubMed]
[43] Manev H., Uz T., Sugaya K., Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J. 2000;14(10):1464–1469. doi: 10.1096/fj.14.10.1464. [PubMed] [Cross Ref]
[44] Misko T.P., Highkin M.K., Veenhuizen A.W., Manning P.T., Stern M.K., Currie M.G., et al. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem. 1998;273(25):15646–15653. doi: 10.1074/jbc.273.25.15646. [PubMed] [Cross Ref]
[45] Virág L., Szabó E., Gergely P., Szabó C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett. 2003;11(140–141):113–124. doi: 10.1016/S0378-4274(02)00508-8. [PubMed] [Cross Ref]
[46] Szabó C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett. 2003;11(140–141):105–112. doi: 10.1016/S0378-4274(02)00507-6. [PubMed] [Cross Ref]
[47] Reed D.J. Regulation of reductive process by glutathione. Biol Chem Pharmacol. 1986;35:7–13. [PubMed]
[48] Aries I, Jakoby WB. Glutathione metabolism and functions. Kroc Found Ser C 1976: 1-382.
[49] Reed D.J., Fariss M.W. Glutathione depletion and susceptibility. Pharmacol Rev. 1984;36:525–533.
[50] Munday R., Winterbourn C.C. Reduced glutathione in combination with superoxide dismutase as an important biological antioxidant defence mechanism. Biochem Pharmacol. 1989;38:4349–4352. doi: 10.1016/0006-2952(89)90641-2. [PubMed] [Cross Ref]
[51] Thifault C., Aumont N., Quirion R., Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem. 1995;65:2725–2733. doi: 10.1046/j.1471-4159.1995.65062725.x. [PubMed] [Cross Ref]
[52] Barker J.E., Heales S.J.R., Cassidy A., BolanÄ os J.P., Land J.M., Clark J.B. Depletion of brain glutathione results in a decrease of glutathione reductase, an enzyme susceptible to oxidative damage. Brain Res. 1996;716:118–122. doi: 10.1016/0006-8993(96)00003-0. [PubMed] [Cross Ref]
[53] Babu G.N., Bawari M. Single microinjection of L-glutamate induces oxidative stress in discrete regions of rat brain. Biochem Mol Biol Int. 1997;43:1207–1217. [PubMed]
[54] Murphy T.H., Schnaar R.L., Coyle J.T. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cysteine uptake. FASEB J. 1990;4:1624–1633. [PubMed]
[55] Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993;16:39–44. doi: 10.1016/0166-2236(93)90070-3. [PubMed] [Cross Ref]
[56] Pereira C.M.F., Oliveira C.R. Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress. Free Radic Biol Med. 1997;23:637–647. doi: 10.1016/S0891-5849(97)00020-8. [PubMed] [Cross Ref]
[57] Kumar A., Seghal N., Padi S.V., Naidu P.S. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicineinduced dysfunction and oxidative stress in rats. Eur J Pharmacol. 2006;551:58–66. doi: 10.1016/j.ejphar.2006.08.076. [PubMed] [Cross Ref]

Articles from Neuroscience Bulletin are provided here courtesy of Springer